I think apparently investors and possibly institutions may have decided that partnering VX-135 is not a good idea. It is possible that they would have thought VRTX would develop it on its own considering it has to share the market with its competitors such as GILD, ABT, SNY, etc. As it is VX 135 was not invented by VRTX but got it from Alios whereby upfront and royalty payments must be made and then to turn around and share any remaing profits with a new partner??? Well, what will be left for VRTX may not amount to much. Third and others, what do you think?
Glad, I think that the nuc will have multiple partner drugs. The share price movement is not a good indicator of what's to come or what investors think. It is manipulated heavily. When Vertex markets 3 or 4 drugs, the manipulation would be dampened.
good thoughts but also, if partnered, the other company will help pay for clinical and production costs helping VRTX to save some money. VRTX won't do a deal if it's not cost effective for them. my other thought is what if some insiders are selling today (boger sells 50K at a clip) and if there isn't volume it pushed the price down. Price down and computers pick up on it and then sell off even more.